Abbott and Bigfoot to develop diabetes technologies in US
Abbott has signed an agreement to integrate its FreeStyle Libre glucose sensing technology with Bigfoot Biomedical’s insulin delivery solutions to develop and commercialise diabetes management systems in the US. Under the agreement, Bigfoot will use the glucose sensing technology to develop personalised, userfriendly systems for optimised insulin delivery and better diabetes management.
The firm will additionally develop systems for auto-titration of its connected insulin injection devices and for automated delivery with its insulin infusion platform.
Bigfoot is currently working on injection and infusion pumpbased insulin delivery systems that employ Internet of Things (IoT) connectivity, smartphone technology, and machine learning to automatically adjust insulin delivery or dosing for optimal glucose range.
Initially launched in 2014 in Europe, the FreeStyle Libre system is currently available in more than 35 countries. A clinical trial incorporating the glucose sensing technology is expected to be conducted next year by Bigfoot in the US.